Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, March 31, 2023.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2023 (2023-03-31): 25.74%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
43.05%
RETURN ON EQUITY (ROE) AVG 3Y
79.24%
RETURN ON EQUITY (ROE) AVG 5Y
79.24%
RETURN ON EQUITY (ROE) AVG 10Y
-82.50%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ironwood Pharmaceuticals, Inc.
Market Cap
$603.31M
Return on Equity (ROE)
N/A
TTM Avg
43.05%
3Y Avg
79.24%
5Y Avg
79.24%
Market Cap
$602.45M
Return on Equity (ROE)
-44.63%
TTM Avg
-42.69%
3Y Avg
-38.09%
5Y Avg
-55.51%
Market Cap
$609.65M
Return on Equity (ROE)
-21.51%
TTM Avg
-20.05%
3Y Avg
-35.91%
5Y Avg
-26.18%
Market Cap
$593.86M
Return on Equity (ROE)
-8.42%
TTM Avg
-4.61%
3Y Avg
-3.17%
5Y Avg
11.46%
Market Cap
$589.21M
Return on Equity (ROE)
-11.56%
TTM Avg
-11.05%
3Y Avg
-6.83%
5Y Avg
-8.10%
Market Cap
$577.37M
Return on Equity (ROE)
N/A
TTM Avg
161.13%
3Y Avg
93.89%
5Y Avg
96.07%
Market Cap
$629.45M
Return on Equity (ROE)
-471.98%
TTM Avg
-147.16%
3Y Avg
-120.43%
5Y Avg
-93.49%
Market Cap
$569.29M
Return on Equity (ROE)
-26.37%
TTM Avg
-3503.18%
3Y Avg
-1722.33%
5Y Avg
3198.08%
Market Cap
$567.21M
Return on Equity (ROE)
40.62%
TTM Avg
9.52%
3Y Avg
-25.24%
5Y Avg
-32.61%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. (IRWD) | $603.31M | N/A | 43.05% | 79.24% | 79.24% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $602.45M | -44.63% | -42.69% | -38.09% | -55.51% |
| AngioDynamics, Inc. (ANGO)vs › | $609.65M | -21.51% | -20.05% | -35.91% | -26.18% |
| Fulgent Genetics, Inc. (FLGT)vs › | $593.86M | -8.42% | -4.61% | -3.17% | 11.46% |
| OrthoPediatrics Corp. (KIDS)vs › | $589.21M | -11.56% | -11.05% | -6.83% | -8.10% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $577.37M | N/A | 161.13% | 93.89% | 96.07% |
| Prime Medicine, Inc. (PRME)vs › | $629.45M | -471.98% | -147.16% | -120.43% | -93.49% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $569.29M | -26.37% | -3503.18% | -1722.33% | 3198.08% |
| CorMedix Inc. (CRMD)vs › | $567.21M | 40.62% | 9.52% | -25.24% | -32.61% |
| Climb Bio, Inc. (CLYM)vs › | $643.06M | -24.06% | -36.09% | -34.99% | -44.03% |
ROE
N/A
ROA
45.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2023-03-31 | 25.74% |
| 2022-12-31 | 26.83% |
| 2022-09-30 | 28.35% |
| 2022-06-30 | 32.48% |
| 2022-03-31 | 101.84% |
| 2021-12-31 | 87.22% |
| 2021-09-30 | 91.44% |
| 2021-06-30 | 99.43% |
| 2021-03-31 | 129.55% |
| 2020-12-31 | 169.50% |
| 2017-03-31 | -407.98% |
| 2016-12-31 | -122.47% |
| 2016-09-30 | -138.32% |
| 2016-06-30 | -118.49% |
| 2016-03-31 | -134.98% |
| 2015-12-31 | -149.98% |
| 2015-09-30 | -165.52% |
| 2015-06-30 | -114.68% |
| 2015-03-31 | -254.12% |
| 2014-12-31 | -214.13% |
| 2014-09-30 | -188.59% |
| 2014-06-30 | -157.75% |
| 2014-03-31 | -120.95% |
| 2013-12-31 | -713.70% |
| 2013-09-30 | -314.31% |
| 2013-06-30 | -111.37% |
| 2013-03-31 | -223.72% |
| 2012-12-31 | -50.42% |
| 2012-09-30 | -19.63% |
| 2012-06-30 | -80.77% |
| 2012-03-31 | -49.99% |
| 2011-12-31 | -59.03% |
| 2011-09-30 | -61.57% |
| 2011-06-30 | -43.93% |
| 2011-03-31 | -38.36% |
| 2010-12-31 | -33.21% |
| 2010-09-30 | -38.82% |
| 2010-06-30 | -39.76% |
| 2010-03-31 | -36.62% |
| 2009-09-30 | -302.22% |
